# A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

> **NCT04703322** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Tenosynovial Giant Cell Tumor

## Interventions

- **DRUG:** Pexidartinib

## Key facts

- **NCT ID:** NCT04703322
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-15
- **Primary completion:** 2023-03-20
- **Final completion:** 2026-05-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04703322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04703322, "A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04703322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*